Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of SARS-CoV-2 hyperimmune intravenous immunoglobulin versus convalescent plasma in healthy adults
ACTRN12620001249943Phase 2Recruiting
- Sponsor
- Aegros
- Start
- Apr 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SARS-CoV-2 hyperimmune intravenous immunoglobulin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Aegros. Primary endpoint: Safety. Started Apr 2021; status: recruiting.
02
Drugs
SARS-CoV-2 hyperimmune intravenous immunoglobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620001249943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001249943.